PubMed Health⌕ Search

Biomedical subjects

N Adrian

Publications and source records attributed to N Adrian.

3 recordsLinked to original sources

Biodegradation of the energetic compound TNT through a multiple-stage treatment approach.

Biodegradation of the energetic compound 2,4,6-trinitrotoluene (TNT) and its intermediate 2,4,6-triaminotoluene (TAT) was investigated in this study. From previous investigations, a relationship between the biological utilization of ethanol as co-substrate for the reduction of TNT under anaerobic conditions was proposed using an anaerobic fluidized-bed reactor (AFBR). In this study, the theoretical co-substrate requirement for reduction of TNT to TAT was further investigated through the systematic lowering of the ethanol loading to the reactor. Near complete reduction to TAT was observed up to a critical ethanol loading point, as well as the production of methane from the limited excess available ethanol. Once ethanol deficient loading conditions were established, the increased presence of incompletely reduced degradation intermediates, such as 2,4-diamino-6-nitrotoluene, and even TNT, was observed. The cessation of methanogenesis confirmed that no excess ethanol was available. Degradation of the TAT intermediate in the reactor effluent was investigated using two second-stage reactors under oxidizing conditions. The first was an aerobic activated sludge reactor, and the second was a denitrifying fluidized-bed reactor (DenFBR). The aerobic reactor was successful in lowering the chemical oxygen demand (COD), but complete removal of TAT was not accomplished. Because of TAT polymerization and auto-oxidation under aerobic conditions, it was difficult to confirm to what extent of TAT removal was biological. In the DenFBR, incompletely reduced TNT intermediates were not successfully degraded, but strong evidence existed for the degradation of TAT. This is the first known report of second stage degradation of TAT under denitrifying conditions.

Aniline Compounds↗

Increased expression of interleukin-12 receptor beta(2) on lamina propria mononuclear cells of patients with active Crohn's disease.

BACKGROUND AND AIMS: Since interleukin-12 is pathogenetically involved in Crohn's disease (CD) but not in ulcerative colitis (UC), expression and mechanisms of induction of interleukin-12 receptor (IL-12R) subunits beta(1) and beta(2) were analyzed in lamina propria mononuclear cells (LPMNC) of patients with CD and UC. PATIENTS AND METHODS: LPMNC from patients with CD ( n=17), UC ( n=14), and controls ( n=19) were isolated by standard techniques. IL-12R beta(1) and IL-12R beta(2) transcripts were semiquantified by RT-PCR, and expression of IL-12R beta(2) chain was characterized by flow cytometry. LPMNC were activated by cross-linking with anti-CD3 antibodies and B7-1 costimulation. RESULTS: IL-12R beta(1) and IL-12R beta(2) transcript concentrations were higher in inflamed specimens than in noninflamed segments of patients with CD but not in UC. Increased percentage of mucosal CD4(+)/IL-12R beta(2)(+) cells was observed in active CD, but not UC. In vitro stimulation of LPMNC with anti-CD3 antibodies resulted in an increase in IL-12R beta(1) transcripts irrespective of B7-1 mediated costimulation (84% and 95%, respectively). However, increased expression of IL-12R beta(2) mRNA (110%) was detected only after B7-1 costimulation. CONCLUSION: Our data indicate that increased mucosal expression of IL-12R beta(2) on LPMNC in CD but not in UC may be the result of B7-1 costimulation. Modulation or inhibition of IL-12R beta(2) expression on LPMNC could provide a selective therapeutic approach in CD.

Adult↗